Frontier Biotechnologies

Frontier Biotechnologies EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Frontier Biotechnologies (688221.SS) as of Oct 17, 2026 is -241.02 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -214.70 M CNY — a change of 12.26% (lower).

EBITDA

-241.02 MCNY

YoY

12.26%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Frontier Biotechnologies is 2025 -241.02 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Frontier Biotechnologies was 2024 -214.70 M CNY. It decreases by 12.26% lower compared to the previous year.

The Frontier Biotechnologies EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-246.05 M CNY
Jan 1, 2019
-162.46 M CNY
Jan 1, 2020
-218.12 M CNY
Jan 1, 2021
-293.59 M CNY
Jan 1, 2022
-350.07 M CNY
Jan 1, 2023
-308.73 M CNY
Jan 1, 2024
-214.70 M CNY
Jan 1, 2025
-241.02 M CNY
The Frontier Biotechnologies EBITDA history
YEAREBITDAYoY
-241.02 MCNY+12.26%
-214.70 MCNY-30.46%
-308.73 MCNY-11.81%
-350.07 MCNY+19.24%
-293.59 MCNY+34.60%
-218.12 MCNY+34.26%
-162.46 MCNY-33.97%
-246.05 MCNY+262.85%
-67.81 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Frontier Biotechnologies Stock analysis

What does Frontier Biotechnologies do? Frontier Biotechnologies Inc is a biotechnology company headquartered in Nanjing, China. It focuses on research, development, production, and sale of medicines. The company has 495 employees and completed its IPO on October 28, 2020. Its products include Aikening and a combination regimen of Albuvirtide (ABT) plus 3BNC117 for HIV treatment, currently in clinical stages. Another clinical-stage product is the transdermal analgesic patch AB001 for muscle, skeleton, and joint pain. The company operates in both domestic and overseas markets. Frontier Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Frontier Biotechnologies stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Frontier Biotechnologies is -241.02 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Frontier Biotechnologies changed from -214.70 M CNY to -241.02 M CNY, representing a 12.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Frontier Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Frontier Biotechnologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Frontier Biotechnologies

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Frontier Biotechnologies